by Cassie Arnold | Jul 14, 2021 | Biotech Finance, Deal making, Digital Health, Digital Therapeutics, Investment, Venture capital
Digital therapeutic deal-making and venture investment continued up and to the right in the first half of 2021 – far up and to the right. On the venture side, Rock Health reported that all digital health companies (including those that don’t have patient-facing...
by Cassie Arnold | Apr 20, 2021 | Deal making, Digital Health, Digital Therapeutic, Investment, Modern Work, Venture capital
For 2021, our data partner DealForma is providing venture investment data in addition to the data they have been sharing on M&A deals. As we all know, VC investment was on a roll in 2020. Silicon Valley Bank has reported that venture investment in...
by Cassie Arnold | Feb 9, 2021 | Biotech Finance, COVID, Deal making, Investment
If you had an inkling that more money went to vaccine and diagnostic companies in 2020, you were right. Diagnostics and vaccines have long been the red-headed stepchildren of life sciences investments. Detecting and treating life threatening diseases is the...
by Cassie Arnold | Jan 28, 2021 | Biotech Finance, Deal making, Digital Health, Digital Therapeutics, Investment
After starting off 2020 with a 35 percent drop in the number of deals from the previous quarter, digital therapeutic deal-making steadily climbed over the course of 2020 to total 71 deals for the year. With 25 deals in the fourth quarter of 2020, the index was up 44...
by Cassie Arnold | Nov 10, 2020 | Biotech Finance, Deal making, Digital Health, Digital Therapeutic
Tired from a long week of parsing electoral college votes? How about focusing on digital therapeutic deals for a change of pace? The third quarter brought a record number of digital therapeutic deals with a total of 19. That’s up from 16 in the previous quarter. The...
by Cassie Arnold | Jul 8, 2020 | Deal making, Digital Health, Digital Therapeutic, Investment
Digital therapeutic dealmaking bounced back to Q4 2019 levels in the second quarter of the year. After a first quarter where deal-making was stymied in by the onslaught of COVID-19, buyers came back big-time in the second quarter once the reality of the “new...
